Daniell Richard 4

What Happened

• Daniell Richard, Executive Vice President, European Commercial at Teva Pharmaceutical Industries Ltd (TEVA), received a grant of 141,478 restricted share units (RSUs) on January 27, 2026. The Form 4 reports the units as a derivative award at $0.00 (no immediate cash paid).
• These units represent contingent rights to receive one ordinary share (or, at the Compensation Committee’s option, the cash value of one ordinary share) at settlement. The units were issued upon satisfaction of performance criteria for performance share units and remain subject to time-based vesting; they are scheduled to vest on March 3, 2026.

Key Details

• Transaction date: 2026-01-27; Transaction type: A (award/grant); reported price: $0.00 (derivative award).
• Shares received: 141,478 restricted share units (contingent rights to ordinary shares or cash).
• Vesting/conditions: These RSUs reflect performance-share-unit satisfaction and remain time-vested, vesting on March 3, 2026 (see footnote).
• Footnotes: F1—each RSU = right to one ordinary share or cash at Committee’s option; F2—these RSUs resulted from satisfied performance criteria and retain time-based vesting (vests 3/3/2026); F3—ordinary shares may be represented by ADS (each ADS currently = 1 ordinary share).
• Ownership after transaction: not specified in the information provided in this summary filing.
• Filing timeliness: Report filed 2026-01-29 for a 2026-01-27 transaction (appears timely).

Context

• This was an equity award (derivative grant), not an open-market purchase or sale—no immediate cash proceeds or sale of shares occurred. For retail investors, awards like this are compensation-related and do not necessarily indicate immediate buying/selling intent by the insider.